Robert Dreicer, MD, MS, MACP, FASCO - Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults

Go online to PeerView.com/GZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Clinicians who treat patients with prostate cancer have new opportunities to improve outcomes across a variety of settings, but the rapid expansion of treatment options has also presented dilemmas for those trying to choose the right treatment for the right patient. For instance, next-generation anti-androgen agents have proven efficacious in early stages of prostate cancer, while approvals of poly (ADP-ribose) polymerase (PARP) inhibitors are available in later-line metastatic castration-resistant prostate cancer (mCRPC). Combination approaches, under investigation across various stages of prostate cancer, further highlight the expansive opportunities for treatment personalization across the disease continuum. Given this new wealth of options, how do clinicians determine the best treatment course for each patient? Join PeerView and the Prostate Conditions Education Council for an expert-led event designed to answer important questions on prostate cancer treatment in the modern era. Combining insight on relevant data from important trials with practical guidance on using guideline-recommended strategies in clinical practice, this event will help clinicians provide optimal personalized care informed by relevant patient-, tumor-, and treatment-related factors and address AEs related to newer therapies and combinations. Upon completion of this CE activity, participants will be able to: Apply current guideline recommendations for germline and tumor testing for clinically relevant biomarkers in patients with prostate cancer, Integrate novel treatment regimens into the management of patients with advanced prostate cancer, based on recent evidence, genetic/molecular features, current guideline recommendations, and individual patient needs and preferences, Employ evidence- and team-based approaches to proactively mitigate and manage treatment-related AEs that may arise in patients receiving novel therapies and combinations for advanced prostate cancer.